| Literature DB >> 35669458 |
Bryan-Josué Flores-Robles1, Eztizen Labrador-Sánchez1, Estíbaliz Andrés-Trasahedo1, Valvanera Pinillos-Aransay1, María-Yasmina Joven-Zapata2, Laura Torrecilla Lerena2, Osman-Alberto Salazar-Asencio3, Juan-Antonio López-Martín1.
Abstract
Introduction: The association of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in a single patient is a rarely described phenomenon. AS and RA are conditions that can have a high impact on the morbidity and mortality of patients.Entities:
Year: 2022 PMID: 35669458 PMCID: PMC9167098 DOI: 10.1155/2022/8500567
Source DB: PubMed Journal: Case Rep Rheumatol ISSN: 2090-6897
Literature review on coexistence of rheumatoid arthritis and ankylosing spondylitis.
| Author | No. | Sex | Age (years) | 1st symptom | Onset (years) | 1st disease | Duration (years) | Nodules | RF | Ac. CCP | HLA B-27 | Lumbar pain | SI | Sind | Eros | Uveitis | Extra-art involv |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wilkinson and Bywaters | 1 | M | 55 | Arthritis | 22 | RA | 33 | + | + | NA | NA | + | + | NS | + | + | 0 |
| Martel and Duff | 2 | M | 47 | Arthritis | 18 | RA | 29 | 0 | + | NA | NA | + | + | 0 | + | 0 | 0 |
| 3 | F | 32 | Arthritis | 30 | RA | 2 | + | + | NA | NA | + | + | + | + | 0 | 0 | |
| 4 | F | 27 | Arthritis | 15 | RA | 12 | + | + | NA | NA | 0 | + | + | + | 0 | 0 | |
| 5 | F | 42 | Arthritis | 24 | RA | 18 | + | + | NA | NA | 0 | + | NS | + | 0 | + | |
| 6 | M | 52 | Arthritis | 21 | RA | 31 | + | + | NA | NA | 0 | + | + | + | 0 | + | |
| 7 | M | 37 | Arthritis | 29 | RA | 8 | 0 | 0 | NA | NA | + | + | NS | + | + | + | |
| 8 | M | 54 | Arthritis | 43 | RA | 9 | + | + | NA | NA | + | 0 | NS | + | 0 | 0 | |
| London and Bland | 9 | M | 26 | Arthritis | 14 | RA | 12 | + | NS | NA | NA | + | + | NS | NS | 0 | 0 |
| Rosenthal et al. [ | 10 | M | 73 | Uveitis | 22 | AE | 51 | + | + | NA | NA | + | + | + | NS | + | + |
| Husskisson et al. [ | 11 | M | 80 | L. pain | 25 | AE | 55 | + | + | NA | NA | + | + | + | + | + | 0 |
| Valkenburgh et al. [ | 12 | F | 45 | Arthritis | 36 | RA | 9 | + | + | NA | NA | + | + | NS | + | + | + |
| Luthrah et al. [ | 13 | M | 59 | L. pain | 34 | AE | 25 | + | + | NA | + | + | + | + | + | 0 | 0 |
| 14 | M | 65 | L. pain | 48 | AE | 17 | + | + | NA | + | + | + | + | + | 0 | 0 | |
| Querol et al. [ | 15 | M | 40 | L. pain | 18 | AE | 22 | 0 | 0 | NA | + | + | + | 0 | 0 | 0 | 0 |
| 16 | F | 46 | L. pain | 27 | AE | 19 | 0 | + | NA | + | + | + | 0 | + | 0 | 0 | |
| 17 | M | 51 | L. pain | 25 | AE | 26 | + | 0 | NA | + | + | + | + | 0 | 0 | 0 | |
| 18 | M | 50 | L. pain | 42 | AE | 8 | 0 | 0 | NA | + | + | + | + | 0 | 0 | 0 | |
| 19 | M | 53 | L. pain | 41 | AE | 12 | + | + | NA | + | + | + | + | + | 0 | 0 | |
| 20 | M | 17 | L. pain | 15 | AE | 2 | 0 | + | NA | + | 0 | + | 0 | + | 0 | 0 | |
| 21 | M | 28 | L. pain | 15 | AE | 13 | 0 | 0 | NA | + | + | + | 0 | 0 | 0 | 0 | |
| Fallet et al. [ | 22 | M | 64 | L. pain | 30 | AE | 34 | + | + | NA | + | + | + | + | + | 0 | 0 |
| 23 | M | 68 | Arthritis | 29 | RA | 39 | 0 | + | NA | + | NS | + | NS | + | + | 0 | |
| 24 | F | 68 | Arthritis | 65 | RA | 3 | + | + | NA | + | 0 | + | NS | 0 | 0 | 0 | |
| 25 | M | 54 | Arthritis | 40 | RA | 14 | + | + | NA | + | + | + | NS | + | 0 | 0 | |
| 26 | M | 67 | Arthritis | 57 | RA | 10 | 0 | + | NA | 0 | + | + | + | + | 0 | 0 | |
| 27 | F | 75 | Arthritis | 63 | RA | 12 | 0 | + | NA | + | + | + | + | + | 0 | 0 | |
| 28 | F | 58 | Uveitis | 42 | RA | 16 | 0 | + | NA | + | 0 | + | NS | + | + | 0 | |
| 29 | M | 68 | L. pain | 29 | AE | 39 | 0 | + | NA | + | + | + | NS | + | 0 | 0 | |
| 30 | M | 44 | Myalgias | 36 | AE | 8 | + | + | NA | + | + | + | NS | + | 0 | 0 | |
| Good et al. [ | 31 | M | NS | L. pain | 29 | AE | NS | 0 | + | NA | + | + | + | + | + | 0 | 0 |
| 32 | M | NS | L. pain | 20 | AE | NS | 0 | + | NA | + | + | + | + | + | 0 | 0 | |
| 33 | M | NS | L. pain | 34 | AE | NS | 0 | + | NA | + | + | + | 0 | + | 0 | 0 | |
| Clayman and Reinertsen | 34 | M | 48 | L. pain | 21 | AE | 27 | + | + | NA | + | + | + | + | 0 | 0 | 0 |
| Espinoza et al. [ | 35 | M | 53 | L. pain | 47 | AE | 6 | + | + | NA | + | + | + | NS | + | 0 | 0 |
| Major et al. [ | 36 | M | 64 | L. pain | 28 | AE | 36 | + | + | NA | + | + | + | + | + | 0 | 0 |
| 37 | M | 61 | L. pain | NS | AE | NS | 0 | + | NA | + | + | + | + | + | 0 | 0 | |
| Lemmer and Irby | 38 | M | 51 | L. pain | 26 | AE | 25 | + | + | NA | + | + | + | + | + | 0 | + |
| Alexander et al. [ | 39 | M | 55 | Arthritis | 32 | RA | 23 | + | + | NA | + | + | + | NS | + | 0 | + |
| 40 | M | 61 | Arthritis | 54 | RA | 7 | + | + | NA | + | 0 | + | + | + | 0 | + | |
| 41 | M | NS | NS | NS | NS | NS | + | + | NA | 0 | NS | + | NS | 0 | 0 | 0 | |
| 42 | M | NS | NS | NS | NS | NS | + | + | NA | 0 | NS | + | NS | + | 0 | 0 | |
| 43 | M | NS | NS | NS | NS | NS | + | + | NA | + | NS | + | NS | + | 0 | 0 | |
| Lavery et al. [ | 44 | M | 60 | L. pain | 18 | AE | 42 | + | + | NA | + | + | + | NS | + | + | + |
| Alarcón Segovia and Martínez-Cordero | 45 | M | 70 | L. pain | NS | NS | NS | + | + | NA | + | + | + | + | + | 0 | 0 |
| Serrano et al. [ | 46 | M | 35 | NS | 22 | RA | 13 | NS | + | NA | + | + | + | NS | NS | 0 | + |
| Fallet et al. [ | 47 | M | 52 | Arthritis | 25 | RA | 27 | 0 | + | NA | + | + | + | + | + | + | + |
| 48 | M | 60 | L. pain | 48 | AE | 12 | + | + | NA | + | + | + | + | + | 0 | 0 | |
| 49 | M | 61 | Arthritis | 40 | NS | 11 | 0 | + | NA | + | 0 | + | 0 | + | 0 | 0 | |
| 50 | M | 56 | L. pain | 22 | AE | 34 | 0 | + | NA | + | + | + | + | + | + | + | |
| 51 | M | 66 | Arthritis | 61 | RA | 5 | + | + | NA | + | + | + | 0 | + | 0 | 0 | |
| 52 | M | 71 | L. pain | 21 | AE | 50 | + | + | NA | + | + | + | + | + | 0 | 0 | |
| 53 | M | 49 | Arthritis | 35 | RA | 14 | 0 | + | NA | + | + | + | 0 | + | 0 | 0 | |
| 54 | F | 83 | Arthritis | 69 | RA | 14 | 0 | + | NA | + | + | + | + | + | 0 | 0 | |
| Helfgott et al. [ | 55 | M | 77 | L. pain | 39 | AE | 38 | + | + | NA | + | + | + | + | + | 0 | 0 |
| Sattar et al. [ | 56 | M | 35 | L. pain | 25 | AE | 10 | 0 | + | NA | 0 | + | + | + | + | + | + |
| Martínez-Cordero et al. [ | 57 | M | 38 | Arthritis | 28 | RA | 10 | NS | + | NA | + | + | + | + | + | 0 | 0 |
| Ferreiro Seoane et al. [ | 58 | M | 44 | L. pain | 31 | AE | 13 | + | + | NA | + | + | + | NS | + | 0 | + |
| Toussirot and Acquaviva | 59 | M | 48 | Arthritis | 22 | RA | 26 | + | + | NA | 0 | 0 | + | 0 | + | 0 | 0 |
| 60 | M | 77 | Arthritis | 35 | RA | 42 | 0 | + | NA | 0 | + | + | + | + | 0 | 0 | |
| 61 | F | 27 | Arthritis | 19 | RA | 8 | 0 | + | NA | + | + | + | 0 | + | 0 | 0 | |
| Genc et al. [ | 62 | F | 62 | Arthritis | 52 | RA | 10 | NS | 0 | NA | + | + | + | + | + | 0 | + |
| Guo et al. [ | 63 | F | 30 | L. pain | 23 | AE | 7 | 0 | + | + | + | + | + | NS | + | 0 | 0 |
| Baksay et al. [ | 64 | F | 57 | L. pain | 25 | AE | 32 | NS | + | + | + | + | + | + | + | 0 | 0 |
| Feijo et al. (2011) | 65 | F | 65 | L. pain | 64 | AE | 1 | 0 | + | + | + | + | + | + | + | 0 | 0 |
| Aghdashi et al. [ | 66 | F | 70 | Arthritis | 58 | RA | 12 | NS | + | + | + | 0 | + | + | + | 0 | 0 |
| Dundar et al. [ | 67 | M | 63 | L. pain | 51 | RA | 12 | NS | + | + | NS | + | + | NS | + | 0 | 0 |
| Koca et al. [ | 68 | F | 38 | L. pain | 38 | RA | 1 | 0 | + | + | 0 | + | + | 0 | 0 | 0 | 0 |
| Barczynska et al. [ | 69 | F | 55 | Arthritis | 35 | RA | 20 | + | + | + | + | + | + | + | + | 0 | 0 |
| 70 | M | 56 | L. pain | 34 | AE | 22 | NS | + | 0 | + | + | + | + | + | 0 | 0 | |
| 71 | M | 65 | NS | NS | NS | NS | NS | + | 0 | + | + | + | + | + | 0 | 0 | |
| Baccouche et al. [ | 72 | F | 21 | L. pain | 20 | AE | 1 | 0 | + | + | + | + | + | + | + | 0 | 0 |
| Sargin and Gurer | 73 | F | 47 | L. pain | 45 | RA | 2 | 0 | NS | NS | NS | + | + | NS | NS | 0 | 0 |
| Haridas and Kiran | 74 | F | 32 | Arthritis | 32 | AR | 1 | 0 | + | + | + | + | + | NS | NS | 0 | 0 |
| Flores-Robles et al. (2020) | 75 | M | 55 | L. pain | 41 | AE | 14 | 0 | + | + | + | + | + | + | 0 | 0 | 0 |
| 76 | F | 43 | Arthritis | 35 | RA | 8 | 0 | + | + | + | + | + | 0 | + | 0 | 0 | |
| 77 | F | 64 | Arthritis | 51 | RA | 13 | 0 | + | + | + | 0 | + | 0 | 0 | 0 | 0 | |
| 78 | M | 57 | Arthritis | 28 | RA | 29 | + | + | + | + | 0 | + | 0 | + | 0 | 0 | |
| 79 | M | 64 | L. pain | 49 | AE | 15 | 0 | + | + | + | + | + | + | 0 | 0 | 0 | |
| 80 | M | 63 | Arthritis | 47 | RA | 16 | 0 | + | + | + | + | + | + | + | 0 | 0 | |
| 81 | F | 75 | Arthritis | 70 | RA | 5 | 0 | + | + | + | + | + | + | + | 0 | 0 |
Ac. CCP: citrullinated peptide antibodies; AE: ankylosing spondylitis; Eros: radiographic erosions on hands and/or feet; extra-art involv: extra-articular involvement; F: female; L. pain: lumbar pain; M: male; NA: not applicable; NS: not specified by the author; RA: rheumatoid arthritis; RF: rheumatoid factor; SI: radiological sacroiliitis; Sind: spine syndesmophytes; sign +: existence/positive; sign 0: absence/negative.
Clinical and epidemiological characteristics of 81 patients with concurrent RA and AE.
|
| |
|---|---|
| Sex | |
| Male | 58 (71.60%) |
| Mean age (years) | 53.72 ± 14.83 |
| Onset mean age (years) | 34.89 ± 14.47 |
| First disease diagnosed | |
| Rheumatoid arthritis | 39/75 (52%) |
| Ankylosing spondylitis | 36/75 (40%) |
| Mean duration of disease (years) | 18.08 ± 13.16 |
| First symptom | |
| Lumbar pain | 37/76 (48.68%) |
| Arthritis | 35/76 (46.05%) |
| Uveitis | 2/76 (2.81%) |
| Rheumatoid nodules | 38/73 (52.05%) |
| Inflammatory lumbar pain | 64/77 (83.12%) |
| Uveitis | 11/81 (13.58%) |
| Extra-articular involvement (except uveitis) | 15/81 (18.51%) |
| Felty syndrome | 4/16 |
| Reactive arthritis | 3/16 |
| Sjögren's syndrome | 2/16 |
| Vasculitis | 2/16 |
| Membranous nephropathy | 2/16 |
| Dermatomyositis | 1/16 |
| Interstitial lung disease | 1/16 |
Mean ± standard deviation.
Radiological, laboratory, and treatment characteristics.
|
| |
|---|---|
| Syndesmophytes (radiograph/MR/CT) | 42/57 (73.68%) |
| Radiographic erosions | 65/76 (85.52%) |
| Radiological sacroiliitis | 80/81 (98.76%) |
| Positive RF | 73/79 (92.40%) |
| Citrullinated peptide antibodies | 16/18 (88.88%) |
| Positive HLA B-27 | 60/67 (89.55%) |
| Treatment | |
| NSAIDs | 28/47 (59.57%) |
| Corticosteroids | 39/47 (82.97%) |
| Gold salts | 12/47 (25.53%) |
| Hydroxychloroquine | 9/47 (19.14%) |
| Sulfasalazine | 9/47 (19.14%) |
| Methotrexate | 15/47 (31.91%) |
| Leflunomide | 4/47 (8.51%) |
| TNF- | 5/47 (10.63%) |
| Others | 6/47 (12.76%) |
CT: computerized tomography; MR: magnetic resonance, NSAIDs: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; TNF-i: tumor necrosis factor inhibitor.